Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 24,579 Shares

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 24,579 shares of the business’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $25.12, for a total value of $617,424.48. Following the completion of the transaction, the director owned 779,652 shares of the company’s stock, valued at $19,584,858.24. This represents a 3.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, October 29th, Ra Capital Management, L.P. sold 251,518 shares of Vor Biopharma stock. The stock was sold at an average price of $25.22, for a total value of $6,343,283.96.
• On Tuesday, October 28th, Ra Capital Management, L.P. sold 124,311 shares of Vor Biopharma stock. The stock was sold at an average price of $27.42, for a total value of $3,408,607.62.
• On Monday, October 27th, Ra Capital Management, L.P. sold 90,941 shares of Vor Biopharma stock. The stock was sold at an average price of $28.12, for a total value of $2,557,260.92.
• On Friday, October 24th, Ra Capital Management, L.P. sold 53,345 shares of Vor Biopharma stock. The shares were sold at an average price of $28.01, for a total value of $1,494,193.45.
• On Thursday, October 23rd, Ra Capital Management, L.P. sold 76,880 shares of Vor Biopharma stock. The shares were sold at an average price of $28.01, for a total value of $2,153,408.80.
• On Tuesday, October 21st, Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma stock. The shares were sold at an average price of $28.11, for a total value of $703,508.97.
• On Monday, October 20th, Ra Capital Management, L.P. sold 92,023 shares of Vor Biopharma stock. The shares were sold at an average price of $29.67, for a total value of $2,730,322.41.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $25.00 on Friday. The stock has a market capitalization of $171.35 million, a PE ratio of -0.09 and a beta of 2.07. Vor Biopharma Inc. has a one year low of $2.62 and a one year high of $65.80. The firm’s fifty day moving average price is $34.14.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Wall Street Analyst Weigh In

Several analysts have issued reports on VOR shares. HC Wainwright boosted their price target on Vor Biopharma to $52.00 and gave the company a “buy” rating in a report on Wednesday. Zacks Research lowered Vor Biopharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Robert W. Baird raised Vor Biopharma from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Finally, Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $76.50.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds have recently made changes to their positions in the business. Ariose Capital Management Ltd bought a new position in shares of Vor Biopharma in the third quarter worth about $5,368,000. XTX Topco Ltd bought a new position in shares of Vor Biopharma in the second quarter worth about $66,000. Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. Jane Street Group LLC bought a new position in shares of Vor Biopharma in the first quarter worth about $140,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma in the first quarter worth about $100,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.